Open Access
CC BY-NC-ND 4.0 · Geburtshilfe Frauenheilkd 2021; 81(12): 1348-1353
DOI: 10.1055/a-1429-2742
GebFra Science
Review/Übersicht

Care of Women with Chronic Inflammatory Bowel Disease (Chronic IBD) During Pregnancy

Recommendations of the Obstetrics and Prenatal Medicine Working Group of the DGGG Article in several languages: English | deutsch
Markus Schmidt
1   Klinik für Frauenheilkunde und Geburtshilfe, Sanakliniken Duisburg, Duisburg, Germany
,
Maritta Kühnert
2   Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum Marburg, Marburg, Germany
,
Bettina Kuschel
3   Klinik und Poliklinik für Frauenheilkunde, Klinikum rechts der Isar, Technische Universität München, München, Germany
,
Sven Kehl
4   Frauenklinik, Universitätsklinikum Erlangen, Erlangen, Germany
,
Ute Margaretha Schäfer-Graf
5   Berliner Diabeteszentrum für Schwangere, St. Joseph Krankenhaus Berlin, Berlin, Germany
› Author Affiliations
Preview

Abstract

The incidence of chronic inflammatory bowel disease (chronic IBD) in persons of reproductive age is high. Chronic IBD does not typically lead to impaired fertility. Nevertheless, the percentage of women suffering from chronic IBD who have children is lower than that of the general population, due to self-imposed childlessness. Providing women with open, unbiased information and, if necessary, helping them to overcome baseless fears should therefore be an essential part of preconception counseling. With the exception of methotrexate, most standard drugs can and should be continued during pregnancy. If the pregnancy occurs during an inactive phase of disease, the rate of complications in pregnancy should, in principle, not be higher than normal. Nevertheless, pregnant women with chronic IBD are classed as high-risk pregnancies. Organ screening in accordance with DEGUM II criteria should be carried out in every case, and women must be monitored for the potential development of placental insufficiency. Any flare-ups which occur during pregnancy should be treated in full. Vaginal delivery can be considered if there is no perianal manifestation of disease; however, the individual risk must be carefully weighed up.



Publication History

Received: 28 February 2021

Accepted after revision: 10 March 2021

Article published online:
08 December 2021

© 2021. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany